Insider Selling: Insulet Co. (NASDAQ:PODD) Director Sells 1,825 Shares of Stock

Insulet Co. (NASDAQ:PODD) Director Wayne A.I. Frederick sold 1,825 shares of the company’s stock in a transaction that occurred on Tuesday, March 25th. The shares were sold at an average price of $275.00, for a total transaction of $501,875.00. Following the completion of the sale, the director now owns 3,231 shares of the company’s stock, valued at approximately $888,525. This trade represents a 36.10 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Insulet Stock Performance

NASDAQ PODD opened at $260.27 on Friday. Insulet Co. has a 52-week low of $160.19 and a 52-week high of $289.46. The company has a debt-to-equity ratio of 1.21, a current ratio of 3.68 and a quick ratio of 2.80. The firm has a market capitalization of $18.28 billion, a price-to-earnings ratio of 44.95, a P/E/G ratio of 3.62 and a beta of 1.29. The company’s fifty day moving average is $272.03 and its two-hundred day moving average is $258.25.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.00 by $0.15. Insulet had a return on equity of 24.46% and a net margin of 20.19%. The business had revenue of $597.50 million for the quarter, compared to analysts’ expectations of $582.02 million. Equities research analysts forecast that Insulet Co. will post 3.92 EPS for the current year.

Analyst Upgrades and Downgrades

PODD has been the subject of a number of research analyst reports. JPMorgan Chase & Co. increased their target price on Insulet from $280.00 to $330.00 and gave the company an “overweight” rating in a report on Thursday, December 12th. Piper Sandler raised their price objective on Insulet from $285.00 to $310.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Canaccord Genuity Group lifted their target price on Insulet from $304.00 to $324.00 and gave the company a “buy” rating in a research note on Friday, February 21st. StockNews.com lowered Insulet from a “buy” rating to a “hold” rating in a report on Tuesday, March 4th. Finally, Wells Fargo & Company boosted their target price on shares of Insulet from $305.00 to $322.00 and gave the stock an “overweight” rating in a research report on Friday, February 21st. Four research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. According to MarketBeat.com, Insulet has a consensus rating of “Moderate Buy” and a consensus target price of $292.06.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Norges Bank bought a new stake in Insulet in the fourth quarter valued at $248,806,000. Raymond James Financial Inc. bought a new stake in Insulet during the fourth quarter worth about $69,433,000. Alecta Tjanstepension Omsesidigt bought a new stake in Insulet during the fourth quarter worth about $53,184,000. Artisan Partners Limited Partnership boosted its holdings in shares of Insulet by 24.1% in the 4th quarter. Artisan Partners Limited Partnership now owns 770,188 shares of the medical instruments supplier’s stock worth $201,073,000 after acquiring an additional 149,524 shares in the last quarter. Finally, Northern Trust Corp increased its holdings in Insulet by 20.5% during the 4th quarter. Northern Trust Corp now owns 738,811 shares of the medical instruments supplier’s stock valued at $192,881,000 after purchasing an additional 125,710 shares in the last quarter.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.